Eltrombopag/eltrombopag principle

Eltrombopag is aTPO receptor agonist, which interacts with the humanTPO receptor(< /span>Also known as cMpl)'s transmembrane region interacts and initiates a signaling cascade that induces megakaryocyte proliferation and differentiation, resulting in increased platelet production. In clinical trials, eltrombopag treatment resulted in a dose-dependent increase in platelet counts following repeated (daily) dosing. Increases in platelet counts were maximal approximately two weeks after initiation of dosing and returned to baseline approximately two weeks after the last dose of eltrombopag.

In healthy adult subjects, eltrombopag was administered at dosages of 50-150 mg/day, dose increasing. Compared with healthy subjects, the AUC of eltrombopag was approximately 1.7 times higher in patients with persistent or chronic ITP and 2.8 times higher in patients with HCV. Steady state was reached after approximately 1 week of once-daily treatment, with a geometric mean accumulation ratio of 75mg/day of 1.56 (90%confidence intervals are 1.20, 1.63). The AUC of eltrombopag was approximately 3.2 times higher in treatment-naïve patients with severe aplastic anemia who received definitive immunosuppressive therapy compared with healthy subjects, indicating that the relative exposure was higher than that in healthy subjects or ITP patients and that the exposure was similar to that in patients with chronic hepatitis C. The plasma AUC of eltrombopag as an oral suspension was higher than that of the tablet formulation.

Eltrombopag absorption reaches peak concentrations between 2 and 6 hours after oral administration. It is estimated that the oral absorption of drug-related substances after a single dose of 75 mg solution is at least 52%. There are generic drugs overseas, each box costs about 400To around 1,000yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0